Meeting
2021 ASCO Annual Meeting
Associations between preexisting nociplastic pain and early discontinuation of aromatase inhibitor therapy in breast cancer.
Authors
Elizabeth Joyce
University of Michigan Health System, Ann Arbor, MI
Elizabeth Joyce , Sidi Wang , Mehrdad Motamed , Kelley M. Kidwell , Norah Lynn Henry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 12068)
DOI
10.1200/JCO.2021.39.15_suppl.12068
Abstract #
12068
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A randomized placebo-controlled phase III study of duloxetine for treatment of aromatase inhibitor (AI)-associated musculoskeletal symptoms in women with early-stage breast cancer: SWOG S1202.
First Author: N. Lynn Henry
Poster
2021 ASCO Annual Meeting
Bone safety profile of steroidal aromatase inhibitor in comparison to non-steroidal aromatase inhibitors in postmenopausal women with breast cancer: A network meta-analysis.
First Author: Shanshan Chen
Poster
2018 ASCO Annual Meeting
Efficacy of omega-3 (ω3) supplementation versus omega-6 (ω6) supplementation for reducing pain among breast cancer survivors: A URCC NCORP RCT.
First Author: Luke Joseph Peppone
Poster
2018 ASCO Annual Meeting
Adherence to hormonal therapy among commercially insured breast cancer patients.
First Author: Hui Zhao